Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the 2020 Evercore ISI HealthCONx Conference on December 1 at 3:30 p.m. ET. The event will be accessible via a live webcast on the Company’s website, with a replay available for 30 days post-presentation. Lantheus is a leader in diagnostic and therapeutic agents, offering products like DEFINITY®, TechneLite®, AZEDRA®, and RELISTOR®. The Company is headquartered in North Billerica, Massachusetts, with additional offices across North America and Europe.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has received FDA approval for its new product, DEFINITY Room Temperature (RT), a room-temperature stable formulation of the existing DEFINITY echocardiography agent. This innovation enhances portability for healthcare providers and addresses a growing need in imaging services. DEFINITY RT, activated using the VIALMIX RFID device, is expected to broaden its clinical use. The composition patent for DEFINITY RT expires in 2035, allowing for significant market presence. Lantheus aims to leverage its microbubble franchise for improved cardiac imaging.
Lantheus Holdings (NASDAQ: LNTH) announced FDA 510(k) clearance for its AI-enabled automated bone scan index (aBSI) on GE Healthcare's Xeleris platform. This approval is pivotal for enhancing diagnostic capabilities in managing advanced prostate cancer. The global licensing agreement allows GE Healthcare to integrate aBSI into its platform, with Lantheus receiving tiered licensing fees. The aBSI product, recognized for its clinical value, automates the detection of metastatic disease hotspots and aids clinical decisions. This partnership could expand Lantheus's reach in precision medicine.
Summary not available.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced executive presentations at two investor conferences in November 2020. The first is the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11, at 9:30 AM ET, featuring CEO Mary Anne Heino and CFO Bob Marshall. The second is the Jefferies Virtual London Healthcare Conference on November 17, at 8:20 AM ET, with CFO Bob Marshall. Live webcasts will be available on the company's website, with replays accessible for 30 days post-event.
Lantheus Holdings (NASDAQ: LNTH) has announced a strategic collaboration with Insightec Ltd. to utilize its microbubbles with Insightec's investigational MR-guided Focused Ultrasound (MRgFUS) platform. This partnership aims to assess treatments for glioblastoma and neurodegenerative diseases by temporarily disrupting the blood-brain barrier to enhance chemotherapy delivery. Lantheus will supply microbubbles, while Insightec handles regulatory submissions and commercialization. The collaboration aligns with Lantheus' growth strategy in oncology and addresses significant unmet medical needs in aggressive cancer treatment.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is set to host a conference call on November 5, 2020, at 8:00 a.m. ET to discuss its Q3 2020 financial and operating results. Interested parties can join the call by dialing 1-866-498-8390 (U.S.) or 1-678-509-7599 (international), using passcode 8872902. A live webcast will also be available on the company's website, with a replay accessible after the call for 30 days. Lantheus is recognized for its innovative diagnostic and therapeutic products, including DEFINITY and TechneLite.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that two abstracts featuring its prostate specific membrane antigen artificial intelligence (PSMA AI) tool will be presented at the upcoming European Association of Nuclear Medicine (EANM) Virtual Congress from October 22-30, 2020. The presentations include an oral presentation on the detection and quantification of 18FDCFPyL PET/CT and an e-poster presentation on deep-learning based bladder segmentation using the same imaging technology. These advancements showcase Lantheus's commitment to innovation in diagnostic imaging.
Lantheus Holdings (NASDAQ: LNTH) has submitted a New Drug Application (NDA) for PyL™, a PET imaging agent for prostate cancer, to the FDA, requesting Priority Review. If granted, this could reduce the review time from 10 months to 6 months. The NDA is backed by data from two pivotal studies (OSPREY and CONDOR), demonstrating PyL's effectiveness in prostate cancer diagnosis. With about 3.2 million men in the U.S. living with prostate cancer, the successful approval and launch of PyL could significantly impact patient management and treatment outcomes.